Roivant Sciences jobs
10 open roles in Roivant Sciences, United States.
Accounting Operations Analyst
3 weeks agoroivantsciencesRoivant Sciences, United StatesRoivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the t
Senior Solution Architect, Finance Systems
30+ days agoroivantsciencesRoivant Sciences, United StatesRoivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the t
Rotational Analyst
30+ days agoroivantsciencesRoivant Sciences, United StatesAbout Roivant Sciences Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2
Senior Analyst / Associate, Commercial
30+ days agoroivantsciencesRoivant Sciences, United StatesUSD 115,000–150,000 / yearRoivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the t
Senior Analyst
30+ days agoroivantsciencesRoivant Sciences, United StatesUSD 115,000–150,000 / yearRoivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the t
Principal, Data & Analytics
30+ days agoroivantsciencesRoivant Sciences, United StatesUSD 130,000–220,000 / yearRoivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the t
Principal, Biostatistician
30+ days agoroivantsciencesRoivant Sciences, United StatesUSD 130,000–220,000 / yearRoivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the t
Founding Engineer, Roivant Health
30+ days agoroivantsciencesRoivant Sciences, United StatesUSD 130,000–180,000 / yearSince its inception in 2014, Roivant Sciences has sought to improve health by rapidly delivering innovative medicines and technologies to patients. We’ve employed a unique, decentralized model of nimble, focused companies (‘Vants’) focused on various therapeutic areas and built around the pursuit of innovation in drug
Principal, Roivant Health
30+ days agoroivantsciencesRoivant Sciences, United StatesUSD 130,000–220,000 / yearSince its inception in 2014, Roivant Sciences has sought to improve health by rapidly delivering innovative medicines and technologies to patients. We’ve employed a unique, decentralized model of nimble, focused companies (‘Vants’) focused on various therapeutic areas and built around the pursuit of innovation in drug
Associate, Roivant Health
30+ days agoroivantsciencesRoivant Sciences, United StatesUSD 135,000–150,000 / yearSince its inception in 2014, Roivant Sciences has sought to improve health by rapidly delivering innovative medicines and technologies to patients. We’ve employed a unique, decentralized model of nimble, focused companies (‘Vants’) focused on various therapeutic areas and built around the pursuit of innovation in drug